Quarterly Report · 10-Q

MapLight Therapeutics, Inc.

MPLTNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 13, 2026Accepted Aug 13, 2026, 5:01 PM EDTCIK 1770069Accession 0001193125-26-349554

Company context

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers.

Current securities

MPLTNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

MapLight Therapeutics, Inc. · 10-Q · Filed 2026-08-13

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Voting Common Stock, par value $0.0001 per share

Symbol: MPLT
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_3debf142-d525-47d5-b306-7f6bfcc4e1b1

Dimensions: Not supplied

Accession 000119312526349554 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.